4:39 PM
 | 
Jan 10, 2019
 |  BC Extra  |  Politics & Policy

No public input from biopharma on emerging tech for export controls

As the comment period for input on how to define emerging technologies under the Export Control Reform Act of 2018 draws to a close Thursday, a lack of publicly available comments from biopharma companies precludes insight into the industry's strategy for protecting its ability to out-license technology to foreign entities.

The U.S. Department of...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >